Off-labelgebruik van biologicals voor zeldzame immunologische aandoeningen
Anne Musters, Amira Assaf, Dominique L.P. Baeten en Sander W. Tas
Patients with serious, immune-mediated inflammatory diseases (IMID's), like sarcoidosis, are increasingly treated with biologicals. Because research in these rare diseases is often very difficult, it is not known in all cases what the effects of the treatment are. In this article we elaborate on the RUBRIC-registry, in which we registrate the efficacy and the safety of these agents.
Endosonography vs conventional bronchoscopy for the diagnosis of sarcoidosis: the GRANULOMA randomized clinical trial
von Bartheld MB, Dekkers OM, Szlubowski A, Eberhardt R, Herth FJ, in 't Veen JC, de Jong YP, van der Heijden EH, Tournoy KG, Claussen M, van den Blink B, Shah PL, Zoumot Z, Clementsen P, Porsbjerg C, Mauad T, Bernardi FD, van Zwet EW, Rabe KF, Annema JT
For the diagnosis of sarcoidosis, identifying granulomas in affected tissue is preferred. This is done by extracting lymph node tissue in the lungs via a biopsy. In this article the investigators evaluated what is the best way to perform the biopsy: with endosonography or with bronchoscopy (which is standard care). The article describes that endosonography is the best way to perform biopsy. Furthermore it describes what kind of complications might be expected.